Currently Viewing:
Newsroom

ADA Issues Time-in-Range Targets for CGM Use

Mary Caffrey
The consensus report was presented at the 79th Scientific Sessions of the American Diabetes Association in San Francisco, California. 
An international panel of experts called for users of continuous glucose monitoring (CGM) to stay within the recommended target range 70% of the time, according to evidence-based guidelines presented Saturday during the 79th Scientific Sessions of the American Diabetes Association (ADA).

For most users, keeping blood glucose levels between 70 mg/dL and 180 mg/dL for 16.8 hours per day would ensure that person’s glycated hemoglobin (A1C) level stays below 7%, the panel reported in a manuscript, “Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time-in-Range.” The paper appeared in Diabetes Care, while its findings were unveiled during ADA in San Francisco, California.

CGM technology has made leaps in recent years, with more accurate sensors and, in some models, factory calibration that free users from needle sticks multiple times a day. While more patients are using CGM—it is considered standard of care for type 1 diabetes (T1D)—the panel concluded that “successful utilization of CGM technology in routine clinical practice remains low.”

Indeed, data presented by the T1D Diabetes Exchange show that A1C levels for this group are rising, even though CGM use has climbed from 7% to 30% between 2010-2012 and 2016-2018. Although A1C levels are generally lower among CGM users, they are worse for other groups, including teenagers. Authors of the Diabetes Care article say that although peer-reviewed articles have established key metrics for CGM use, formal adoption of guidelines by diabetes professional organizations did not follow—until now.

In recent years, both clinical researchers and advocacy groups have pressed for time in range to gain recognition as a key measure in diabetes care, one that should have consideration alongside A1C as a marker of glycemic control and overall health.

The paper’s lead author, Tadej Battelino, MD, head of the department of pediatric and adolescent endocrinology at Ljubljana University Medical Centre in Slovenia, described the use of time-in-range as a complement to A1C. But others see time-in-range as so important that it may someday replace A1C as the best indicator of future complications.

Leading diabetes researcher and clinician Anne Peters, MD, professor of medicine at the Keck School of Medicine at the University of Southern California, went so far as to say that "probably the A1C is a useless number” during a meeting of The Institute for Value-Based Medicine® presented by The American Journal of Managed Care® in April.

Development of time-in-range guidelines took shape in February 2019 when the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel that included physicians, researchers, and people living with diabetes. Subgroups formed to review literature and make evidence-based recommendations for each population, which were presented to the full panel and put to a vote. Modifications to the general recommendations were made for older and high-risk users, and those using CGM during pregnancy.



 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up